SNG-100 is under clinical development by Seanergy Dermatology and currently in Phase I for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase I drugs for Atopic Dermatitis (Atopic Eczema) have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SNG-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SNG-100 is under development for the treatment of moderate atopic dermatitis. It is administered through topical route. The drug candidate is a combination of low potency steroid and skin barrier repair agent.
For a complete picture of SNG-100’s drug-specific PTSR and LoA scores, buy the report here.